Loading news...
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) saw a large decline in short interest in the month of January. As of January 30th, there was short interest totaling 120,341 shares, a decline of 34.8% from the January 15th total of 184,605 shares. Approximately 0.0% of the shares of the company are sold short. Based on
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Merck KGaA (MKKGY) or Madrigal (MDGL). But which of these two stocks presents investors with the better value opportunity right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 0.1% of Merck KGaA
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 241,637 shares, an increase of 234.9% from the November 30th total of 72,150 shares. Based on an average daily volume of 280,839 shares, the
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Profitability This table compares Merck KGaA and BioCryst
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) shares saw an uptick in trading volume on Friday following a better than expected earnings announcement. 608,868 shares changed hands during mid-day trading, an increase of 330% from the previous session's volume of 141,732 shares.The stock last traded at $27.07 and had previously closed at $28.19. The company
Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Florian Schraeder - Head of Investor Relations Belén Garijo López - Chair of Executive Board & CEO Helene von Roeder - CFO & Member of Executive Board Danny Bar-Zohar - Member of the Executive Board & CEO of Healthcare Kai Beckmann - Deputy CEO of Electronics & Member of the Executive Board Jean Wirth - Member of the Executive Board & CEO Life Science Conference Call Participants Matthew Weston - UBS Investment Bank, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Shyam Kotadia - Goldman Sachs Group, Inc., Research Division Charles Pitman - Barclays Bank PLC, Research Division Peter Verdult - BNP Paribas, Research Division Oliver Metzger - ODDO BHF Corporate & Markets, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and United Therapeutics (UTHR). But which of these two stocks is more attractive to value investors?
Merck KGaA (MKGAF) is deeply undervalued, offering a compelling entry point with strong fundamentals and resilience to AI disruption. MKGAF's diversified segments—life science, healthcare (biologics), and electronics—provide recurring revenue and benefit from both pharma and AI-driven chip demand. Despite near-term EPS declines and electronics headwinds, stabilization is expected, with long-term EPS growth and valuation recovery projected from 2026 onward.
President Donald Trump on Thursday announced a deal with EMD Serono, a subsidiary of German drugmaker Merck KGaA, that aims to cut the out-of-pocket costs for in vitro fertilization, with the move coming more than a year after his campaign promise to eliminate all such costs for the fertility treatment.
President Donald Trump announced two new efforts to expand availability of in vitro fertilization, the first concrete step from the Trump administration on the expensive, decades-old procedure. It includes a deal with Germany's Merck KGaA to slash the price of some of the company's fertility medicines in exchange for relief from planned tariffs on pharmaceuticals imported into the U.S.,
President Donald Trump announces a deal with Germany's Merck KGaA to cut the price of some of its fertility medicines in exchange for relief from threatened tariffs. He speaks during a a press conference in the Oval Office.
The company confirmed its 2025 guidance and is targeting annual organic sales growth in the mid-single-digit percentage range and an expansion in profitability over the medium term.
German pharmaceuticals and technology company Merck KGaA slightly improved its mid-term guidance for its healthcare business ahead of its capital markets day on Thursday.
Police in China are investigating an app fraud case, said German healthcare firm Merck KGaA , amid growing concerns over entities claiming affiliation with major corporations.